Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients

Anti‐Pneumocystis prophylaxis is recommended for at least 6–12 months after solid organ transplantation, as most cases of Pneumocystis jirovecii pneumonia (PCP) occur during the first year post transplantation. Herein, we report 4 cases of late‐onset PCP (>1 year post transplant). PCP appeared in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplant infectious disease 2014-04, Vol.16 (2), p.324-328
Hauptverfasser:	Perez-Ordoño, L., Hoyo, I., Sanclemente, G., Ricart, M.J., Cofan, F., Perez-Villa, F., de la Bellacasa, J. Puig, Moreno, A., Cervera, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Infective Agents - therapeutic use Female Humans late-onset opportunistic infection lymphopenia Male Middle Aged Organ Transplantation - adverse effects PCP Pneumocystis Pneumocystis carinii Pneumocystis jirovecii Pneumonia, Pneumocystis - diagnosis Pneumonia, Pneumocystis - drug therapy Pneumonia, Pneumocystis - microbiology rituximab solid organ transplantation Time Factors Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anti‐Pneumocystis prophylaxis is recommended for at least 6–12 months after solid organ transplantation, as most cases of Pneumocystis jirovecii pneumonia (PCP) occur during the first year post transplantation. Herein, we report 4 cases of late‐onset PCP (>1 year post transplant). PCP appeared in a range of 50–68 months post transplant. Two cases had history of humoral rejection episodes treated with rituximab, and the other 2 had low CD4+ T‐cell count (
ISSN:	1398-2273 1399-3062
DOI:	10.1111/tid.12184